Jean-Baptiste Thibert: Protecting Fundamental Human Rights to Improve Patient Access and Donor Health
Jean-Baptiste Thibert, Medical and Biology Director at EFS, shared a post on LinkedIn recent article he and his colleagues co-authored, adding:
“Excited to share our latest collaborative work on protecting fundamental human rights, thereby improving both patient access to plasma-derived therapies and donor health protection.
Patient access to plasma-derived medicinal products and blood donor protection are challenges that are currently hard to meet and often presented like mutually exclusive choices.
We show how advantageous it could be to reposition the fundamental right to health protection as an input parameter for decisions on the transfusion and plasma supply chain.
Placing both patients and donors under the umbrella of fundamental human rights allows to act not as if a choice has to be made between patients and donors, but in ways that protect them both.”
Katja van den Hurk, Head of Donor Studies and Senior Epidemiologist/Principal Investigator at Sanquin, Professor of Donor Health at University of Amsterdam, shared this post on LinkedIn, adding:
“Happy to see this collaborative work published!
Our paper discusses how placing patients and donors under the same human-rights framework can help address challenges in plasma supply; supporting both access to plasma-derived medicinal products and donor health protection.”
Title: Protection of fundamental human rights by improving patient access to plasma-derived therapies and donor health protection
Authors: Jean-Baptiste Thibert, Leni von Bonsdorff, Jean-Philippe Plançon, Vincenzo de Angelis, Cynthia So-Osman, Christian Erikstrup, Pierre Tiberghien, Katja van den Hurk
Read the Full Article on Vox Sanguinis
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 25, 2026, 20:01Anand Gupta: Timing of DOAC Initiation in Newly Diagnosed Atrial Fibrillation
-
Sep 25, 2026, 19:56Steven Fein: A History of Blood Clots Doesn’t Mean a Healthy Pregnancy Is Out of Reach
-
Sep 25, 2026, 19:54Pedro Perez: “Provoked” VTE May Not Always Mean the Risk Disappears When the Provoking Event Does
-
Sep 25, 2026, 19:53Kemal Karaagac: Calcitriol May Reduce Thrombotic Risk in MASLD
-
Sep 25, 2026, 19:52The SINGLE-AF Trial Anticoagulation for Intermediate Stroke Risk – NEJM
-
Sep 25, 2026, 19:49Shinya Goto: DOAC vs Placebo in Intermediate Stroke Risk of AF in Single Country?
-
Sep 25, 2026, 19:47Bryan Cotton: DOACs Versus Nothing When Stroke Risk Is Not Zero
-
Sep 25, 2026, 19:45Selin Yaman Seval: ITP Is More Than a Low Platelet Count
-
Sep 25, 2026, 19:44Cy R. Wilkins: Treating Chemotherapy-Induced Thrombocytopenia Beyond the Platelet Count